Losartan Potassium Tablet, Film Coated
Product Images NDC 72865-142

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 72865-142). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xlcare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100mg 1000s

Losartan Potassium Tablets, USP is a prescription drug manufactured by XLCare Pharmaceuticals, Inc. It is used to lower blood pressure and improve the chances of survival after a heart attack. It contains 100mg of losartan potassium. The medication should be stored at room temperature and kept away from children. Please consult the package insert for full prescribing information.*

FDA Label Image

100mg 30s

Losartan Potassium Tablets are manufactured by XLcare Pharmaceuticals Inc. Each coated tablet contains 100 mg of Losartan Potassium USP. They are dispensed by pharmacists with a patient information leaflet. Dosage information and storage instructions are included in the package insert. The medication should be kept in a tightly closed container and protected from light. The warning advises keeping the medication out of reach of children. Manufactured for XLCare Pharmaceuticals, Inc., it is made by Ascent Pharmaceuticals, Inc. at Central sip, New York. The manufacturing date is 07/20.*

FDA Label Image

100mg 90s

XLcare Pharmaceuticals Inc. Losartan Potassium Tablets, USP, containing 100mg of Losartan Potassium USP per coated tablet. Dispense the Patient Information Leaflet provided separately to each patient. Usual adult dosage and storage instructions are provided in the package insert. Manufactured by Ascent Pharmaceuticals, Inc. for XLCare Pharmaceuticals, Inc. Keep the container tightly closed and protect from light. WARNING: Keep this and all medications out of the reach of children.*

FDA Label Image

25mg 1000s

This is a description of Losartan Potassium Tablets, USP from XLcare Pharmaceuticals. The tablets come in a container of 1000 and are only available through a prescription. Each film-coated tablet contains 25 mg of Losartan potassium USP. It is advised to store between 20°- 25°C (68° to 77°F). Further instructions and warnings can be found in the package insert. This product is manufactured for XLcare Pharmaceuticals in Lawrenceville, GA and produced by Ascent Pharmaceuticals, Inc. in Central Islip, NY. Ensure the container is tightly closed and protected from light. The medication should be kept away from children.*

FDA Label Image

25mg 30s

Losartan Potassium Tablets, USP is a prescription medication manufactured by XLcare Pharmaceuticals Inc. Each film-coated tablet contains 25mg of losartan potassium USP, and the usual adult dosage should be checked with the prescribing information provided. The medication should be stored between 20°C to 25°C (66°F to 77°F) and protected from light. The medication comes in 30 tablets per bottle, and the pharmacist should dispense the Patient Information Leaflet to each patient. The medication should be kept away from the reach of children. The manufacturer is XLCare Pharmaceuticals, Inc., and it's manufactured for Ascent Pharmaceuticals Inc. The address of XLcare Pharmaceuticals Inc. is 242 South Culver Street, Suite 202, Lawrenceville, GA 30046.*

FDA Label Image

25mg 90s

Losartan Potassium Tablets are a medication used to treat high blood pressure. Each film-coated tablet contains 25mg of losartan potassium USP. It is important for pharmacists to dispense the Patient Information Leaflet provided separately to each patient. The usual adult dosage should be followed while referring to the full prescribing information provided inside the package. The medication should be stored within 20° to 25°C (68° to 77°F) and kept away from children. The manufacturer is XLCare Pharmaceuticals, Inc., based in Lawrenceville, GA, while Ascent Pharmaceuticals, Inc. is responsible for its production in Central Islip, NY.*

FDA Label Image

50mg 1000s

XLcare is a pharmaceutical product that comes in the form of film-coated tablets that contain 50 mg of losartan potassium USP. The usual adult dosage and further prescribing information can be found in the package insert. Losartan potassium should be stored at room temperature in a tightly closed container and protected from light. There is a warning to keep this medication out of reach of children. XLCare Pharmaceuticals, Inc. is the manufacturer of this product and the patient information leaflet is provided separately to each patient. The product is dispensed by pharmacists and is available only with a prescription.*

FDA Label Image

50mg 30s

This is a drug label for Losartan Potassium Tablets, USP manufactured by XLcare Pharmaceuticals Inc. Each film-coated tablet contains 50mg of Losatan potassium USP. The usual adult dosage is indicated on the package insert or full prescribing information. The tablets are sold in a container with 30 tablets and should be stored at controlled room temperature. The medication should be kept out of the reach of children. The pharmaceutical company is located in Lawrenceville, GA and the drug is manufactured by Ascent Pharmaceuticals, Inc. in Central Islip, NY.*

FDA Label Image

50mg 90s

FDA Label Image

Fig1

The text is describing a study comparing the effectiveness of two drugs, Atenolol and Losartan Potassium, in reducing the primary endpoint among patients. They found that Losartan Potassium had a 13% risk reduction compared to Atenolol, with a p-value of 0.021. The study was conducted over a period of 66 months, with data collected at each month interval from 6 to 66 months.*

FDA Label Image

Fig2

This appears to be a chart or graph showing the percentage of patients who experienced a fatal or non-fatal stroke while taking either Atenolol or Losartan Potassium. It also includes an adjusted risk reduction percentage for stroke with Losartan Potassium and a corresponding p-value. The numbers under "Study Month" suggest that this is a time-based analysis of stroke occurrence.*

FDA Label Image

Fig3

The text provides a statistical figure showing the primary endpoint events within demographic subgroups. The figure includes information on the primary composite stroke, fatal/non-fatal events, hazard ratio, and population rate for different demographic categories. The symbols in the figure are proportional to the sample size. The information is adjusted for baseline Framingham risk score and left ventricular hypertrophy. The figure includes data on various ethnicities.*

FDA Label Image

Fig4

FDA Label Image

Tab1

This is a table outlining the results of two studies on different medications - HCTZ, Losartan, and Lisinopril - and their associated rates of coughing as a side effect. Study 1 shows that 25% of participants experienced coughing with HCTZ, 17% with Losartan, and 69% with Lisinopril. Study 2 shows that 35% of participants on placebo reported coughing, while those on Losartan and Lisinopril reported rates of 29% and 62%, respectively. Demographic information is also provided for each study, including the percentage of participants who were Caucasian and female.*

FDA Label Image

Tab2

This is a table displaying pharmacokinetic parameters in hypertensive adults and children aged 6 to 16 following multiple dosing. The table shows the results of a study where 25 adults were given 50mg once daily, and children were given 0.7mg/kg once daily for 7 days. The table shows the values of parent and active metabolite in A0C (g/ml), with mean and standard deviation, harmonic mean and standard deviation, and median.*

FDA Label Image

Tab3

This is a table showing the incidence of primary and secondary endpoint events on a study using Losartan and Atenolol. The primary composite endpoints were stroke, myocardial infarction, and cardiovascular mortality, while the secondary endpoint events were stroke, myocardial infarction, cardiovascular mortality, death due to coronary heart disease or stroke, and other causes. The table also shows the percentages, risk, and p-values.*

FDA Label Image

Tab4

The table shows the incidence of primary endpoint events related to the effects of Losartan and Placebo. The primary composite endpoint event is shown to have an incidence reduction of 16.1% in patients who consumed Losartan compared to Placebo. The doubling of serum creatinine, end-stage renal disease (ESRD), and death as a first event are analyzed for Losartan and Placebo resulting in higher incidences of these events among Placebo consumers. Overall incidence of doubling of serum creatinine, ESRD, and death are also analyzed, and Losartan consumers showed a lower incidence rate than Placebo.*

FDA Label Image

Tab5

The table presents efficacy outcomes within demographic subgroups for the primary composite ESRD endpoint in patients taking Losartan and Placebo. The subgroups are categorized based on their age, gender, and race. The table displays the number of patients, event rate, hazard ratio, and the 95% confidence interval for each subgroup.*

FDA Label Image

Struct

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.